AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30727012 — intervention group
Group type: COMPARATOR
Intervention: Cell saving (CS)
Number of subjects: 48
Study 30439793 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid method for predicting therapeutic targets for hypertension
Number of subjects: 320
Study 30439793 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid method for predicting therapeutic targets for dyslipidemia
Number of subjects: 320
Study 30439793 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid method for predicting therapeutic targets for diabetes
Number of subjects: 320
Study 27924398 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxabact® OC5 (O. formigenes)
Number of subjects: 28
Study 27924398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 26341759 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk-and-eat intervention (n = 30; nurse-supervised walking three times per week and weekly nutritional advice)
Number of subjects: 59
Study 26341759 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 29; control group)
Number of subjects: 59
Study 23550171 — intervention group
Group type: EXPERIMENTAL
Intervention: Eclipse 3
Number of subjects: 21
Study 23550171 — intervention group
Group type: EXPERIMENTAL
Intervention: EverGo
Number of subjects: 21
Study 23550171 — intervention group
Group type: EXPERIMENTAL
Intervention: iGo
Number of subjects: 21
Study 23550171 — intervention group
Group type: COMPARATOR
Intervention: Control walk using the subject's current oxygen system
Number of subjects: 21
Study 21273893 — intervention group
Group type: COMPARATOR
Intervention: Inpatient rehabilitation (CR_In)
Number of subjects: 54
Study 21273893 — intervention group
Group type: COMPARATOR
Intervention: Inpatient rehabilitation with ambulatory training (CR_In+Amb)
Number of subjects: 54
Study 21273893 — intervention group
Group type: COMPARATOR
Intervention: Control group (CR_In declined rehabilitation)
Number of subjects: 54
Study 19685258 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine via antecubital vein at 140 microg kg(‐1) min(‐1) (A140)
Number of subjects: 50
Study 19685258 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine via antecubital vein at 170 microg kg(‐1) min(‐1) (A170)
Number of subjects: 50
Study 19685258 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine via femoral vein at 140 microg kg(‐1) min(‐1) (F140)
Number of subjects: 50
Study 17909210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 0
Study 17909210 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 17909210 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 0
Study 17909210 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary rehabilitation
Number of subjects: 0
Study 17909210 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 17909210 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 0
Study 17909210 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (Viniyoga)
Number of subjects: 0
Study 17909210 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional restoration
Number of subjects: 0
Study 17909210 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial heat
Number of subjects: 0
Study 15257845 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 1443
Study 15257845 — intervention group
Group type: COMPARATOR
Intervention: Minimum Intervention (MI)
Number of subjects: 1443
Study 11799305 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional needle placement and manipulation
Number of subjects: 68
Study 11799305 — intervention group
Group type: COMPARATOR
Intervention: New placebo device
Number of subjects: 68
Study 9504568 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (100 microg) daily by subcutaneous injection for up to 90 days
Number of subjects: 216
Study 9504568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 8070510 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg naftopidil
Number of subjects: 12
Study 8070510 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 29420390 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted Jump-Squat Training (WJST)
Number of subjects: 48
Study 29420390 — intervention group
Group type: COMPARATOR
Intervention: Body Mass Squat Jump Training (BMSJT)
Number of subjects: 48
Study 26569545 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture (TA)
Number of subjects: 17
Study 26569545 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 17
Study 26569545 — intervention group
Group type: COMPARATOR
Intervention: True acupuncture (TA) and Sham acupuncture (SA)
Number of subjects: 17
Study 24872875 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual medical care
Number of subjects: 180
Study 24872875 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized manual therapy and rehabilitative exercise
Number of subjects: 180
Study 24872875 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based group exercise
Number of subjects: 180
Study 22669400 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intradermal absorbable sutures (A)
Number of subjects: 206
Study 22669400 — intervention group
Group type: COMPARATOR
Intervention: Interrupted nonabsorbable sutures (NA)
Number of subjects: 206
Study 19943988 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency tonsillectomy
Number of subjects: 50
Study 19943988 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrocautery tonsillectomy
Number of subjects: 50
Study 19943988 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 50
Study 17972135 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative esophageal manometry studies
Number of subjects: 145
Study 17972135 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative esophageal pH studies
Number of subjects: 145
Study 15747253 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 100
Study 15747253 — intervention group
Group type: COMPARATOR
Intervention: Stavudine
Number of subjects: 100
Study 12794785 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant pain treatment group (OTG; n = 40)
Number of subjects: 61
Study 12794785 — intervention group
Group type: COMPARATOR
Intervention: Standardized medical program with emphasis on physical therapy (PTG; n = 21)
Number of subjects: 61
Study 10808734 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 10 mg
Number of subjects: 168
Study 10808734 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 20 mg
Number of subjects: 168
Study 10808734 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (two-week treatment)
Number of subjects: 168
Study 10808734 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mononitrate 40 mg daily for two weeks
Number of subjects: 168
Study 10808734 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 168
Study 10808734 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 168
Study 10808734 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (two-week therapy)
Number of subjects: 168
Study 10808734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 40-80 mg daily for two weeks
Number of subjects: 168
Study 8779382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnelling of the epidural catheter subcutaneously for a distance of 5 cm
Number of subjects: 82
Study 8779382 — intervention group
Group type: COMPARATOR
Intervention: Standard method of fixation with a transparent adhesive dressing
Number of subjects: 82
Study 8779382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnelling of the epidural catheter
Number of subjects: 82
Study 2005691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical BCG (50 mg weekly for 6 weeks, at 8, 10, and 12 weeks, at 6 months and every 6 months thereafter)
Number of subjects: 66
Study 2005691 — intervention group
Group type: COMPARATOR
Intervention: Intravesical plus percutaneous BCG (50 mg intravesical BCG weekly for 6 weeks, at 8, 10, and 12 weeks, at 6 months and every 6 months thereafter)
Number of subjects: 66
Study 6661772 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium‐meglumin‐joxaglat (Hexabrix)
Number of subjects: 24
Study 6661772 — intervention group
Group type: COMPARATOR
Intervention: sodium‐meglumin‐diatrizoat (Urografin 76)
Number of subjects: 24
Study 29348694 — intervention group
Group type: EXPERIMENTAL
Intervention: Democratic deliberation (DD) group
Number of subjects: 0
Study 29348694 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (written materials)
Number of subjects: 0
Study 29348694 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27401363 — intervention group
Group type: EXPERIMENTAL
Intervention: PREPARE intervention (review PREPARE and an easy-to-read advance directive)
Number of subjects: 0
Study 27401363 — intervention group
Group type: COMPARATOR
Intervention: Control arm (only the easy-to-read advance directive)
Number of subjects: 0
Study 27401363 — intervention group
Group type: EXPERIMENTAL
Intervention: PREPARE intervention
Number of subjects: 0
Study 24610312 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort (SJW) co-administered with boceprevir
Number of subjects: 17
Study 24610312 — intervention group
Group type: COMPARATOR
Intervention: Boceprevir alone
Number of subjects: 17
Study 22460142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 1 mg
Number of subjects: 140
Study 22460142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 3 mg
Number of subjects: 140
Study 22460142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg
Number of subjects: 140
Study 22460142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg
Number of subjects: 140
Study 22460142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 20149584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger extract (120 mg)
Number of subjects: 32
Study 20149584 — intervention group
Group type: COMPARATOR
Intervention: Control (1 g of coconut oil as placebo)
Number of subjects: 32
Study 18497189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health promotion program (tooth brushing 2 times/day, use of fluoridated toothpastes, dental care visits)
Number of subjects: 9
Study 18497189 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 9
Study 15812606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) in combination with fluvoxamine
Number of subjects: 30
Study 15812606 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) in combination with placebo
Number of subjects: 30
Study 15812606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) in combination with fluvoxamine or placebo
Number of subjects: 30
Study 12420344 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan (750 mg pure chitosan per tablet, two tablets three times daily before each main meal)
Number of subjects: 50
Study 12420344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical placebo tablets)
Number of subjects: 50
Study 10624755 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue protrusion during posterior rhinomanometry (PRM)
Number of subjects: 32
Study 10624755 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue protrusion during PRM
Number of subjects: 32
Study 7653757 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.3 mg administered into the systemic circulation at 10% recovery (Group 2)
Number of subjects: 15
Study 7653757 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.3 mg given when twitch height recovered to 50% depression (Group 3)
Number of subjects: 15
Study 7653757 — intervention group
Group type: COMPARATOR
Intervention: Control group with tourniquet released after 3-4 min (Group 1)
Number of subjects: 15
Study 1952297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentigetide nasal solution (1 mg into each nostril four times daily)
Number of subjects: 431
Study 1952297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentigetide nasal solution
Number of subjects: 431
Study 1952297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 6820917 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of MMC immediately after operation
Number of subjects: 3030
Study 6820917 — intervention group
Group type: EXPERIMENTAL
Intervention: Futraful for one year after MMC administration
Number of subjects: 3030
Study 6820917 — intervention group
Group type: EXPERIMENTAL
Intervention: Futraful alone for long-term
Number of subjects: 3030
Study 6820917 — intervention group
Group type: EXPERIMENTAL
Intervention: Futraful (dosage increase)
Number of subjects: 3030
Study 6820917 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC and futraful combination
Number of subjects: 3030
Study 6820917 — intervention group
Group type: EXPERIMENTAL
Intervention: Futraful
Number of subjects: 3030
Study 30779395 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin-prescribed patients
Number of subjects: 73
Study 30779395 — intervention group
Group type: COMPARATOR
Intervention: Never–statin‐prescribed patients
Number of subjects: 73
Study 29085998 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory condition
Number of subjects: 12
Study 29085998 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal condition
Number of subjects: 12
Study 29085998 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory condition
Number of subjects: 12
Study 27852303 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa
Number of subjects: 40
Study 27852303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24817517 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative breast MRI (n = 220)
Number of subjects: 440
Study 24817517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breast MRI, n = 220)
Number of subjects: 440
Study 23153062 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrostimulation (60 minutes, wave frequency 20 Hz, pulse duration 20 us, two times a day until discharge)
Number of subjects: 30
Study 23153062 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional rehabilitation only)
Number of subjects: 30
Study 20601741 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (isoleucine:leucine:valine = 1:2.3:1.2) at 100 mg/kg body weight
Number of subjects: 12
Study 20601741 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 12
Study 20601741 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrin at 100 mg/kg body weight)
Number of subjects: 12
Study 20601741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18945398 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body skills group program (12 sessions)
Number of subjects: 82
Study 18945398 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 82
Study 16355623 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 2% Zanthoxylum Nitidum extract
Number of subjects: 200
Study 16355623 — intervention group
Group type: COMPARATOR
Intervention: Common toothpaste (Control)
Number of subjects: 200
Study 12648732 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 60
Study 12648732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10986363 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with autism
Number of subjects: 2
Study 10986363 — intervention group
Group type: COMPARATOR
Intervention: Typically developing children
Number of subjects: 2
Study 8960576 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-induced vasodilation in patients with CAD
Number of subjects: 25
Study 8960576 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin administration
Number of subjects: 25
Study 8960576 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA administration
Number of subjects: 25
Study 8251721 — intervention group
Group type: EXPERIMENTAL
Intervention: 100ml Naoxuenin (NXN) oral liquid with conventional treatment
Number of subjects: 42
Study 8251721 — intervention group
Group type: COMPARATOR
Intervention: Current conventional treatment
Number of subjects: 42
Study 3762902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine vasopressin (0.4 ml, 23 IU per day in 3 divided doses for 15 days)
Number of subjects: 40
Study 3762902 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.2 ml, 20 micrograms per day in a single dose for 15 days)
Number of subjects: 40
Study 3762902 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered by nasal route)
Number of subjects: 40
Study 30714983 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga based mind-body intervention (MBI) with DMARDs
Number of subjects: 72
Study 30714983 — intervention group
Group type: COMPARATOR
Intervention: Control group (DMARDs only)
Number of subjects: 72
Study 29087796 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash prepared from Pomegranate extract, 15 ml twice a day
Number of subjects: 40
Study 29087796 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash prepared from Grape seed extract, 15 ml twice a day
Number of subjects: 40
Study 29087796 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash prepared from Guava extract, 15 ml twice a day
Number of subjects: 40
Study 29087796 — intervention group
Group type: COMPARATOR
Intervention: Control - Distil water, twice a day
Number of subjects: 40
Study 27581531 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring group (oral prasugrel 5 mg daily with dose or drug adjustment)
Number of subjects: 877
Study 27581531 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (oral prasugrel 5 mg daily with no monitoring or treatment adjustment)
Number of subjects: 877
Study 27581531 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring group
Number of subjects: 877
Study 27581531 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 877
Study 25194227 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (20 and 50mg p.o.)
Number of subjects: 15
Study 25194227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 22248751 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lactate clearance rate protocol
Number of subjects: 62
Study 22248751 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% lactate clearance rate protocol
Number of subjects: 62
Study 22248751 — intervention group
Group type: COMPARATOR
Intervention: Control group (6-hour EGDT strategy)
Number of subjects: 62
Study 20034605 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H1N1 vaccine containing 5.25 microg haemagglutinin (HA)
Number of subjects: 130
Study 20034605 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted H1N1 vaccine containing 21 microg HA
Number of subjects: 130
Study 20034605 — intervention group
Group type: COMPARATOR
Intervention: AS03(A)-adjuvanted H1N1 vaccine
Number of subjects: 130
Study 20034605 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted H1N1 vaccine
Number of subjects: 130
Study 17697209 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-1001 (12 mg)
Number of subjects: 21
Study 17697209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 16123474 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 21
Study 16123474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11852667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10-20 mg/day for 12 weeks
Number of subjects: 21
Study 10431553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting homocysteine levels in normohomocysteinaemic individuals
Number of subjects: 42
Study 10431553 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-methionine homocysteine levels in normohomocysteinaemic individuals
Number of subjects: 42
Study 10431553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting homocysteine levels variation in individuals homozygous for the 677 C‐‐>T mutation
Number of subjects: 42
Study 10431553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-individual variability of plasma homocysteine levels
Number of subjects: 42
Study 10431553 — intervention group
Group type: EXPERIMENTAL
Intervention: Average post-methionine homocysteine levels
Number of subjects: 42
Study 7780090 — intervention group
Group type: COMPARATOR
Intervention: 12 months of chemotherapy with rifampicin-isoniazid-ethambutol (ethambutol only for the first 6 months)
Number of subjects: 28
Study 7780090 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 months of chemotherapy with rifampicin-isoniazid-ethambutol (ethambutol only for the first 6 months)
Number of subjects: 28
Study 11659330 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of risks and benefits of Carbamazepine
Number of subjects: 39
Study 11659330 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up interviews after disclosure
Number of subjects: 39
Study 7359305 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (verbal aggression towards a stranger)
Number of subjects: 48
Study 7359305 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (pain tolerance procedure)
Number of subjects: 48
Study 31995561 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency
Number of subjects: 24
Study 31995561 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnancies (control group)
Number of subjects: 24
Study 30760581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fevipiprant (DP2 antagonist)
Number of subjects: 0
Study 30760581 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 28381796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 12
Study 28381796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine with valproic acid
Number of subjects: 12